Which has preferable valuation and earnings, OVID or AAPG?

Ovid Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ovid Therapeutics $7.25M 59.57 -$17.41M -$0.29 N/A Ascentage Pharma Group International $574.12M 2.74 -$177.71M N/A N/A

Does the media favor OVID or AAPG?

In the previous week, Ovid Therapeutics had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Ovid Therapeutics and 3 mentions for Ascentage Pharma Group International. Ovid Therapeutics' average media sentiment score of 0.96 beat Ascentage Pharma Group International's score of 0.54 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STOK or OVID?

In the previous week, Stoke Therapeutics had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 5 mentions for Ovid Therapeutics. Stoke Therapeutics' average media sentiment score of 1.23 beat Ovid Therapeutics' score of 0.96 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OVID or SRPT?

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.96 beat Sarepta Therapeutics' score of 0.69 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMCR or OVID?

In the previous week, Immunocore had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for Immunocore and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.96 beat Immunocore's score of 0.66 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, TRLV or OVID?

Trulieve Cannabis has higher revenue and earnings than Ovid Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.42 N/A N/A N/A Ovid Therapeutics $7.25M 59.57 -$17.41M -$0.29 N/A

Does the media prefer TRLV or OVID?

In the previous week, Ovid Therapeutics had 4 more articles in the media than Trulieve Cannabis. MarketBeat recorded 5 mentions for Ovid Therapeutics and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 1.94 beat Ovid Therapeutics' score of 0.96 indicating that Trulieve Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ovid Therapeutics (OVID) Competitors

$2.31 +0.09 (+4.23%)

As of 10:51 AM Eastern

Compare

OVID vs. AAPG, STOK, SRPT, IMCR, and TRLV

Should you buy Ovid Therapeutics stock or one of its competitors? MarketBeat compares Ovid Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ovid Therapeutics include Ascentage Pharma Group International (AAPG), Stoke Therapeutics (STOK), Sarepta Therapeutics (SRPT), Immunocore (IMCR), and Trulieve Cannabis (TRLV).

How does Ovid Therapeutics compare to Ascentage Pharma Group International?

Ovid Therapeutics (NASDAQ:OVID) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Ovid Therapeutics had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Ovid Therapeutics and 3 mentions for Ascentage Pharma Group International. Ovid Therapeutics' average media sentiment score of 0.96 beat Ascentage Pharma Group International's score of 0.54 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	59.57	-$17.41M	-$0.29	N/A
Ascentage Pharma Group International	$574.12M	2.74	-$177.71M	N/A	N/A

Ovid Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Ascentage Pharma Group International has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ascentage Pharma Group International's return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Ascentage Pharma Group International	N/A	N/A	N/A

Ovid Therapeutics presently has a consensus price target of $5.38, indicating a potential upside of 132.28%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 175.70%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats Ovid Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Ovid Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

72.2% of Ovid Therapeutics shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Stoke Therapeutics currently has a consensus price target of $43.00, indicating a potential upside of 47.48%. Ovid Therapeutics has a consensus price target of $5.38, indicating a potential upside of 132.28%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Stoke Therapeutics had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 5 mentions for Ovid Therapeutics. Stoke Therapeutics' average media sentiment score of 1.23 beat Ovid Therapeutics' score of 0.96 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Ovid Therapeutics has a net margin of -240.11% compared to Stoke Therapeutics' net margin of -529.20%. Ovid Therapeutics' return on equity of -22.51% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Stoke Therapeutics has higher revenue and earnings than Ovid Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$32.08M	56.61	-$6.89M	-$2.81	N/A
Ovid Therapeutics	$7.25M	59.57	-$17.41M	-$0.29	N/A

Summary

Ovid Therapeutics beats Stoke Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Sarepta Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ovid Therapeutics currently has a consensus target price of $5.38, indicating a potential upside of 132.28%. Sarepta Therapeutics has a consensus target price of $24.72, indicating a potential upside of 61.65%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Ovid Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14

Sarepta Therapeutics has a net margin of -2.94% compared to Ovid Therapeutics' net margin of -240.11%. Sarepta Therapeutics' return on equity of 7.56% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Ovid Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	59.57	-$17.41M	-$0.29	N/A
Sarepta Therapeutics	$2.20B	0.73	-$713.41M	-$0.96	N/A

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.96 beat Sarepta Therapeutics' score of 0.69 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Summary

Ovid Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Immunocore currently has a consensus price target of $56.29, suggesting a potential upside of 69.71%. Ovid Therapeutics has a consensus price target of $5.38, suggesting a potential upside of 132.28%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Immunocore had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for Immunocore and 5 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.96 beat Immunocore's score of 0.66 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Ovid Therapeutics has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$412.81M	4.09	-$35.51M	-$0.55	N/A
Ovid Therapeutics	$7.25M	59.57	-$17.41M	-$0.29	N/A

Immunocore has a net margin of -6.68% compared to Ovid Therapeutics' net margin of -240.11%. Immunocore's return on equity of -7.07% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ovid Therapeutics beats Immunocore on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Trulieve Cannabis has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Trulieve Cannabis' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Trulieve Cannabis presently has a consensus target price of $15.00, indicating a potential upside of 73.31%. Ovid Therapeutics has a consensus target price of $5.38, indicating a potential upside of 132.28%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

72.2% of Ovid Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Trulieve Cannabis has higher revenue and earnings than Ovid Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.42	N/A	N/A	N/A
Ovid Therapeutics	$7.25M	59.57	-$17.41M	-$0.29	N/A

In the previous week, Ovid Therapeutics had 4 more articles in the media than Trulieve Cannabis. MarketBeat recorded 5 mentions for Ovid Therapeutics and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 1.94 beat Ovid Therapeutics' score of 0.96 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats Trulieve Cannabis on 8 of the 13 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$433.01M	$11.49B	$6.81B	$12.55B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-8.00	796.38	282.12	24.83
Price / Sales	59.57	749.10	573.08	78.59
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	2.31	10.32	11.02	6.15
Net Income	-$17.41M	$2.81B	$3.49B	$347.61M
7 Day Performance	-1.53%	2.14%	0.47%	1.17%
1 Month Performance	-13.98%	-1.98%	-4.24%	-3.46%
1 Year Performance	362.80%	157.82%	62.63%	19.43%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.1821 of 5 stars	$2.31 +4.2%	$5.38 +132.3%	+344.0%	$433.01M	$7.25M	N/A	60
AAPG Ascentage Pharma Group International	4.0636 of 5 stars	$18.75 +2.0%	$46.43 +147.7%	-53.2%	$1.75B	$82.10M	N/A	600	News Coverage
STOK Stoke Therapeutics	2.7553 of 5 stars	$28.15 +1.7%	$43.00 +52.8%	+123.5%	$1.75B	$184.42M	N/A	100	Positive News
SRPT Sarepta Therapeutics	3.5189 of 5 stars	$16.44 -2.3%	$23.90 +45.5%	-6.6%	$1.74B	$2.20B	N/A	1,372	Upcoming Earnings
IMCR Immunocore	3.3576 of 5 stars	$34.07 +0.0%	$56.71 +66.5%	+2.5%	$1.74B	$400.02M	N/A	320	Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. AAPG, STOK, SRPT, IMCR, and TRLV

How does Ovid Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Ovid Therapeutics compare to Stoke Therapeutics?

Summary

How does Ovid Therapeutics compare to Sarepta Therapeutics?

Summary

How does Ovid Therapeutics compare to Immunocore?

Summary

How does Ovid Therapeutics compare to Trulieve Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. AAPG, STOK, SRPT, IMCR, and TRLV

How does Ovid Therapeutics compare to Ascentage Pharma Group International?

Does the media favor OVID or AAPG?

Which has preferable valuation and earnings, OVID or AAPG?

Which has more risk & volatility, OVID or AAPG?

Is OVID or AAPG more profitable?

Do analysts rate OVID or AAPG?

Do insiders and institutionals believe in OVID or AAPG?

Summary

How does Ovid Therapeutics compare to Stoke Therapeutics?

Do insiders and institutionals believe in STOK or OVID?

Do analysts rate STOK or OVID?

Does the media prefer STOK or OVID?

Which has more volatility and risk, STOK or OVID?

Is STOK or OVID more profitable?

Which has preferable earnings & valuation, STOK or OVID?

Summary

How does Ovid Therapeutics compare to Sarepta Therapeutics?

Do institutionals & insiders hold more shares of OVID or SRPT?

Do analysts rate OVID or SRPT?

Is OVID or SRPT more profitable?

Which has better valuation & earnings, OVID or SRPT?

Does the media favor OVID or SRPT?

Which has more risk and volatility, OVID or SRPT?

Summary

How does Ovid Therapeutics compare to Immunocore?

Do analysts prefer IMCR or OVID?

Does the media refer more to IMCR or OVID?

Which has more risk and volatility, IMCR or OVID?

Which has preferable earnings and valuation, IMCR or OVID?

Is IMCR or OVID more profitable?

Do insiders and institutionals hold more shares of IMCR or OVID?

Summary

How does Ovid Therapeutics compare to Trulieve Cannabis?

Is TRLV or OVID more profitable?

Do analysts prefer TRLV or OVID?

Do insiders & institutionals believe in TRLV or OVID?

Which has stronger valuation & earnings, TRLV or OVID?

Does the media prefer TRLV or OVID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools